EverydayHealth teams up with PsychCentral.com

Share this article:
Consumer health portal EverydayHealth.com reached a content syndication deal with mental health Web site PsychCentral.com.

Financial terms of the deal were not disclosed.

PsychCentral.com will share selections of its original news and information with Everyday

Health.com, which also serves as PsychCentral.com’s official advertising rep.

“This deal allows us to better service our advertisers and gives us broader reach in a category where there’s tremendous demand,” EverydayHealth VP Ezra Doty told MM&M. “It gives us the ability to put together more customized programs so we can perform and deliver the kind of results our clients have come to expect…It’s the right audience for our advertisers.”

PsychCentral.com CEO Dr. John Grohol added, “We were looking for a partner to expose a little bit more of the world of mental health to a broader consumer base. Yes, you have pharmaceutical advertising on general health Web sites like EverydayHealth but it will probably be better targeted and more actionable when it’s published on PsychCentral.com.”

EverydayHealth—which claims 7.4 million users—provides health and wellness info from its 40 condition channels.

PsychCentral.com, with an estimated 600,000 users a month,  features original, peer-reviewed editorial content and news.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...